The development to date for those who are just joining the thread.
http://www.clpmag.com/2015/01/abbott...cer-biomarker/
"Abbott currently offers the only FDA-approved urine-based molecular test for bladder cancer, UroVysion, which is included in the National Comprehensive Cancer Network and European Association of Urology guidelines.
The FGFR3 mutation analysis assay will be available in early 2015. Abbott is also in the process of developing reagents for further studies, and is exploring collaborations with pharmaceutical companies to leverage the FGFR3 test as a companion diagnostic for emerging bladder cancer therapies."